CTNM News & Events

Contineum Therapeutics announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the Journal of Medicinal Chemistry. The article, "Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid Receptor 1 (LPAR1) Antagonist with Slow Tight Binding Characteristics for the Treatment of Neuroinflammatory Disorders," highlights the Company's internally discovered, selective LPAR1 antagonist as a potentially best-in-class approach for the treatment of fibrotic conditions. "This was an incredible effort by our discovery team to enable the exploration of the full potential of LPAR1 as a therapeutic target for a wide range of indications," said Daniel Lorrain, Ph.D., Chief Scientific Officer, Contineum Therapeutics. "PIPE-791's chemical structure facilitates a slow on-off rate for our compound, differentiated pharmacokinetics and sustained, high target coverage. We believe these unique properties will allow us to pursue a potentially best-in-class approach in several inflammatory and fibrotic diseases."

Cash, cash equivalents and marketable securities were $246.3 million as of March 31, 2026. Contineum believes its cash resources are sufficient to fund its planned operations through mid-2029. "We're excited to have recently shared positive topline results from our chronic pain trial," said Carmine Stengone, CEO, Contineum Therapeutics. "We continue to steadily enroll PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF). With a projected cash runway that extends through mid-2029, which is approximately one year past the estimated completion of our IPF trial, we are maintaining a disciplined approach to capital allocation that prioritizes our lead clinical indication, while thoughtfully considering the advancement of other programs."

Contineum Therapeutics reported positive topline data from its exploratory Phase 1b trial of PIPE-791, a potentially best-in-class selective antagonist of the lysophosphatidic acid 1 (LPA1) receptor, for the non-opioid treatment of chronic osteoarthritis pain or chronic low back pain. The randomized, double-blind, placebo-controlled, 4-week, crossover trial enrolled 43 patients (23 COAP and 20 CLBP). The trial design incorporated a washout period for patients prior to the first 4-week treatment period (TP1), after which patients crossed over immediately into a second 4-week treatment period (TP2) without an intervening PIPE-791 washout. PIPE-791 was administered orally at 10mg once-daily.